ArticleJournal of Alzheimer's disease : JAD2013
PET imaging of neuropathology in tauopathies: progressive supranuclear palsy.
Article in Journal of Alzheimer's disease : JAD, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- Tau-PET imaging in Parkinson's disease: a systematic review and meta-analysis.Frontiers in neurology · 2023Pooled it
- A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism.European journal of nuclear medicine and molecular imaging · 2016Pooled it
- Nuclear Medicine Imaging Biomarkers in Parkinson's Disease: Past, Present, and Future Directions.Medical sciences (Basel, Switzerland) · 2025Review
- A brief history of Aβ imaging.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Brainstem and cerebellar radiological findings in progressive supranuclear palsy.Brain communications · 2025Review
- Planimetric and Volumetric Brainstem MRI Markers in Progressive Supranuclear Palsy, Multiple System Atrophy, and Corticobasal Syndrome. A Systematic Review and Meta-Analysis.Neurology international · 2023Review
- Striatal dopaminergic lesions contributed to the disease severity in progressive supranuclear palsy.Frontiers in aging neuroscience · 2022Article
- Imaging pathological tau in atypical parkinsonisms: A review.Clinical parkinsonism & related disorders · 2022Review
- An Update on the State of Tau Radiotracer Development: a Brief Review.Molecular imaging and biology · 2021Review
- The role of neuroimaging in Parkinson's disease.Journal of neurochemistry · 2021Review
- Article
- Tau-PET imaging as a molecular modality for Alzheimer's disease.American journal of nuclear medicine and molecular imaging · 2021Article
- Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy.Annals of neurology · 2020Article
- Positron Emission Tomography (PET) and Neuroimaging in the Personalized Approach to Neurodegenerative Causes of Dementia.International journal of molecular sciences · 2020Review
- Bibliometric Analysis of Chronic Traumatic Encephalopathy Research from 1999 to 2019.International journal of environmental research and public health · 2020Article
- Aβ Plaques.Free neuropathology · 2020Article
- Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes.Frontiers in neurology · 2020Review
- The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention?Acta neuropathologica communications · 2019Review
- The Value of In Vitro Binding as Predictor of In Vivo Results: A Case for [Molecular imaging and biology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveCurrently [18F]FDDNP is the only PET imaging probe with the ability to visualize hyperphosphorylated tau fibrillar aggregates in living subjects. In this work, we evaluate in vivo [18F]FDDNP labeling of brain neuropathology, primarily tau fibrillar aggregates, in patients with progressive supranuclear palsy (PSP), a human tauopathy usually lacking amyloid-β deposits.
methodsFifteen patients with PSP received [18F]FDDNP PET scanning. [18F]FDDNP distribution volume ratios, in reference to cerebellar gray matter, were determined for cortical and subcortical areas and compared with those of patients with Parkinson's disease with short disease duration, and age-matched control subjects without neurodegenerative disorders.
results[18F]FDDNP binding was present in subcortical areas (e.g., striatum, thalamus, subthalamic region, midbrain, and cerebellar white matter) regardless of disease severity, with progressive subcortical and cortical involvement as disease severity increased. Brain patterns of [18F]FDDNP binding were entirely consistent with the known pathology distribution for PSP. High midbrain and subthalamic region [18F]FDDNP binding was distinctive for PSP subjects and separated them from controls and patients with Parkinson's disease.
conclusionsThese results provide evidence that [18F]FDDNP is a sensitive in vivo PET imaging probe to map and quantify the dynamic regional localization of tau fibrillar aggregates in PSP. Furthermore, [18F]FDDNP PET may provide a tool to detect changes in tau pathology distribution either associated with disease progression or as a treatment biomarker for future tau-specific therapies. Patterns of [18F]FDDNP binding may also be useful in diagnosis early in disease presentation when clinical distinction among neurodegenerative disorders is often difficult.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.